Endonovo Therapeutics Inc announces sales of SofPulse units to multiple plastic surgery centers.
The FDA-cleared SofPulse is a non-invasive device utilized for the reduction of postoperative pain and edema. It represents a low-cost drug-free solution for reducing opioid usage, accelerating patient recovery and preventing opioid addiction following surgical procedures. This non-invasive and non-pharmacologic therapy has no known side effects and presents no potential for overdose or dependency as SofPulse is not reliant on any narcotic to produce pain and edema reduction, according to the company in a news release.
“SofPulse main distribution model is marketing to major hospitals throughout the US and is beginning to be viewed as the standard of care for postoperative pain and edema reduction for numerous inpatient hospital procedures. With the expansion of our customer base and recent orders from numerous plastic surgery centers, SofPulse demonstrates different applications for its use,” says Endonovo Therapeutics CEO Alan Collier, in the release.
“Many of the plastic surgery centers have state-of-the-art surgical suites and recovery rooms equipped to hospital standards, and we continue working with these centers and completing evaluations. Although in the nascent stages of expanding into fully certified office-based surgery centers, we recognize the large and growing market size allowing us to be well poised to capitalize on this opportunity,” he adds.
[Source(s): Endonovo Therapeutics Inc, Financial Buzz]